Elafibranor

Peroxisome Proliferator-activated Receptor Agonist — ALIMENTARY TRACT AND METABOLISM

Key facts

Elafibranor is an onp drug in the Peroxisome Proliferator-activated Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2024. Its mechanism of action is classified as Cytochrome P450 3A4 Inducers and Peroxisome Proliferator-activated Receptor Agonists. DrugCentral lists 4 molecular targets, including PPARA, PPARG and PPARD. Recorded indications include Primary biliary cholangitis.

• Approval status: onp (first approved 2024 by the FDA).
• Drug class: Peroxisome Proliferator-activated Receptor Agonist.
• Mechanism of action: Cytochrome P450 3A4 Inducers; Peroxisome Proliferator-activated Receptor Agonists.
• Molecular targets: PPARA, PPARG, PPARD and Nlrp3 (4 listed in DrugCentral).
• Indications: Primary biliary cholangitis.
• ATC code: A05AX06 (Other drugs for bile therapy).
• Molecular formula: C22H24O4S; molecular weight 384.50 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Primary biliary cholangitis

Mechanism & targets

• Mechanism of action (MoA): Cytochrome P450 3A4 Inducers; Peroxisome Proliferator-activated Receptor Agonists
• Established pharmacologic class: Peroxisome Proliferator-activated Receptor Agonist

Molecular targets (4)

Target	Gene	Action	Activity
Peroxisome proliferator-activated receptor alpha	PPARA	agonist	EC50 7.34
Peroxisome proliferator-activated receptor gamma	PPARG	agonist	EC50 6.84
Peroxisome proliferator-activated receptor delta	PPARD	agonist	EC50 6.75
NACHT, LRR and PYD domains-containing protein 3	Nlrp3	unknown	IC50 4.40

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2024-10-19	EMA	—	Ipsen Pharma	Yes
2024-06-10	FDA	—	Ipsen Biopharmaceuticals, Inc.	Yes

ATC classification

ATC code	Therapeutic hierarchy
A05AX06	ALIMENTARY TRACT AND METABOLISM › BILE AND LIVER THERAPY › BILE THERAPY › Other drugs for bile therapy

Chemical structure

• Molecular formula: C₂₂H₂₄O₄S
• Molecular weight: 384.50 g/mol
• CAS number: —
• InChIKey: AFLFKFHDSCQHOL-IZZDOVSWSA-N
• PubChem CID: 9864881

CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)/C=C/C(=O)C2=CC=C(C=C2)SC

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Elafibranor used for?

DrugCentral lists the following indications for Elafibranor: Primary biliary cholangitis.

How does Elafibranor work?

Elafibranor is classified as Cytochrome P450 3A4 Inducers and Peroxisome Proliferator-activated Receptor Agonists; its molecular targets in DrugCentral include PPARA (agonist), PPARG (agonist), PPARD (agonist) and Nlrp3.

When was Elafibranor first approved?

Elafibranor was first approved by the FDA in 2024.

What drug class does Elafibranor belong to?

Elafibranor is in the Peroxisome Proliferator-activated Receptor Agonist class.

What is the chemical formula of Elafibranor?

Elafibranor has the molecular formula C22H24O4S and a molecular weight of 384.50 g/mol.

Sources

• DrugCentral drug card 5824 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3707395 — compound record and bioactivity
• PubChem CID 9864881 — chemical identifiers
• DrugBank DB05187 — drug record
• FDA UNII 2J3H5C81A5 — substance identity
• DailyMed: FDA labels for Elafibranor — current prescribing information (label search)
• UniProt Q07869 (PPARA) — target protein
• UniProt P37231 (PPARG) — target protein
• UniProt Q03181 (PPARD) — target protein

How this page is built: methodology · editorial policy & corrections.